Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding executive share awards rather than a financial performance report.
Material Changes
The material change reported is the award of Ordinary Shares to Mrs. V A Whyte on February 24, 2011. The specific awards were:
- 2009 Share Value Plan: 10,050 shares
- 2009 Performance Share Plan: 11,800 shares
The Performance Share Plan award was calculated using an Ordinary Share price of £11.78, representing the closing price on February 24, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total number of shares awarded to Mrs. V A Whyte (21,850 total) against the company's internal equity records.
- Confirm the share price of £11.78 used for the Performance Share Plan valuation matches the market close on February 24, 2011.
- Ensure the notification date of February 25, 2011, complies with the required disclosure timelines under Rule 3.1.4R(1)(a).